Effect of ASV and DCV Therapy on the Quality of Immune Status in Chronic HCV Patients

Trial Profile

Effect of ASV and DCV Therapy on the Quality of Immune Status in Chronic HCV Patients

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Oct 2015

At a glance

  • Drugs Asunaprevir (Primary) ; Daclatasvir (Primary)
  • Indications Hepatitis C
  • Focus Pharmacodynamics
  • Acronyms ImmunoDual
  • Most Recent Events

    • 16 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 07 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top